Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials.

BACKGROUND The aim of the study was to evaluate the outcome of acute myeloid leukaemia (AML) in patients with a previous malignancy (sAML) treated with chemo- and/or radiotherapy, enrolled in conventional trials. PATIENTS AND METHODS In a multicentre setting, a prospective non-concurrent analysis was performed on 2513 new AML patients, aged 12-78 years, consecutively enrolled in EORTC-GIMEMA trials between 1987 and 2001. Thirty-eight patients with sAML were identified and compared with a group of 114 de novo AML patients matched according to age, French-American-British criteria, white blood cell count at diagnosis, trial and time of diagnosis of AML. Induction treatment response, disease-free survival (DFS), duration and overall survival (OS) were evaluated in the two groups. RESULTS Comparing the complete remission (CR) rate between 38 sAML patients and 114 de novo AML patients, selected according to the previously reported criteria, we observed no difference in the CR rates [25/38 (66%) versus 66/114 (58%); Pearson chi(2) 0.7393, P=0.390] as well as no differences while comparing the DFS and the OS between the two groups. CONCLUSION The results of this study suggest that sAML patients are characterised by a good performance status permitting their recruitment in conventional trials without a previous myelodysplastic phase. Similar to de novo AML patients, sAML patients show good response to treatment and the possibility of cure.

[1]  W. Hiddemann,et al.  Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Diehl,et al.  Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[4]  F. Behm,et al.  Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. , 2003, Blood.

[5]  B. Johansson,et al.  Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001 , 2002, Leukemia.

[6]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[7]  J. Friedberg,et al.  Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. , 2002, Blood.

[8]  M. Vignetti,et al.  Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. , 2002, Blood.

[9]  J. Rowe.  Therapy of secondary leukemia , 2002, Leukemia.

[10]  E. Estey,et al.  Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors , 2002, Leukemia.

[11]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[12]  A. Levis,et al.  Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Levis,et al.  Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia , 2001, British journal of haematology.

[14]  M. Lazzarino,et al.  Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.

[15]  M. Labopin,et al.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.

[16]  M. Labopin,et al.  Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Bone marrow transplantation.

[17]  M. Andersen,et al.  Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality. , 1998, Haematologica.

[18]  R. Storb,et al.  Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. , 1997, Blood.

[19]  F. Mandelli,et al.  EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML). , 1994, Leukemia & lymphoma.

[20]  H. Tilly,et al.  Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Rowley,et al.  Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. , 1993, The New England journal of medicine.

[22]  F. Mandelli,et al.  Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. , 1992, Leukemia.

[23]  F. Behm,et al.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. , 1991, The New England journal of medicine.

[24]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[25]  C. Demur,et al.  Association of the Philadelphia chromosome and 5q- in secondary blood disorder. , 1988, Cancer genetics and cytogenetics.

[26]  R. Larson,et al.  Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. , 1988, Blood.

[27]  H. Hansen,et al.  RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy , 1987, The Lancet.

[28]  R. Larson,et al.  High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Kantarjian,et al.  Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Simon,et al.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Karp,et al.  Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.